Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

P. M. Fracasso, K. A. Blum, M. K. Ma, B. R. Tan, L. P. Wright, S. A. Goodner, C. L. Fears, W. Hou, M. A. Arquette, J. Picus, Alex Denes, J. E. Mortimer, L. Ratner, S. P. Ivy, H. L. McLeod

Research output: Contribution to journalArticle

27 Scopus citations
Original languageEnglish (US)
Pages (from-to)46-53
Number of pages8
JournalBritish Journal of Cancer
Volume93
Issue number1
DOIs
Publication statusPublished - Jul 11 2005
Externally publishedYes

    Fingerprint

Keywords

  • Doxil
  • Multidrug resistance
  • Pegylated liposomal doxorubicin
  • PSC 833
  • Valspodar

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fracasso, P. M., Blum, K. A., Ma, M. K., Tan, B. R., Wright, L. P., Goodner, S. A., ... McLeod, H. L. (2005). Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. British Journal of Cancer, 93(1), 46-53. https://doi.org/10.1038/sj.bjc.6602653